Location: Lebanon, NH
Type: InternshipMin. Experience: Student (College)
We are the leading provider of therapeutic antibody discovery and engineering technologies, focusing solely on our partners without pursuing an internal product pipeline. This includes naïve discovery from synthetic libraries in yeast or B cells (mice and humans), antibody engineering and optimization, multi-specific antibody engineering, and a portfolio of proprietary CD3 antibodies licensed non-exclusively for bispecific applications. Since 2009, we have partnered with over 80 pharmaceutical and biotechnology companies, generating more than 360 therapeutic programs, over 40 clinical programs, and our first approved product. Our technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, Novo Nordisk, and Takeda. Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Regeneron, Sanofi, Takeda and others. We have also partnered with many early-stage venture-backed companies, including Amagma, Cygnal, Dragonfly, iOmx, NextPoint, Pliant, Tizona, TRex Bio and others, as well as mid-size public biopharmaceutical companies such as Acceleron, Alector, Cullinan Oncology, Five Prime, Innovent, Jounce, Mersana, Scholar Rock, Surface Oncology, and others.
Our integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. We offer fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. We enable our partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
